BENLYSTA® (BELIM	umab) Prescriber Or	DER FORM					
Fax	completed form, insurance in	formation, and	clinical documentat	ion to:			
	Patient Name:				Date of Birth:		
option care health [™]	Address:						
	Phone:		Height:	□ inches □	cm Weight:	□ lbs □ kg	
		Clinical	Information				
Primary Diagnosis Description:			ICD-10 Code:				
		BENLYSTA® (BELII	MUMAB) Prescripti	on			
BENLYSTA® (BELIMUMAE	B) refill as directed x 1 year	·	·				
Loading Dose:	IV: Infuse 10mg/kg over 1 hou	ır every 2 weeks	for 3 doses.				
Maintenance Dose:	IV: Infuse 10mg/kg over 1 hou	ır every 4 weeks					
		Ancilla	ary Orders				
Anaphylaxis Kit			,				
■ Di	oinephrine 0.3 mg (> 30 kg), 0.1 phenhydramine 25 mg (> 30 kg ormal saline 500 mL (> 30 kg) o RN headache rated > 5 on pain	g) or 1.25 mg/kg (r 250 mL (≤ 30 kg	(≤ 30 kg – 25mg max	x dose) IV or IM;	repeat x 1 in 15 min I	PRN no improvement.	
	650 mg PO 30 min before infus e 25 mg PO 30 min before infu	-					
IV Flush Orders <u>Peripheral:</u> <u>Implanted Por</u>	NS 2 to 3 mL pre-/pos rt: NS 5 to 10 mL pre-/po For maintenance, hep	ost-use and 10 to					
Lab Orders No labs ordere	ed at this time.						
☐ Other:							
Refill above ancillary orde	ers as directed x 1 year.						
Skilled nurse to assess an will provide ongoing supp	d administer via access device port as needed.	as indicated abov	ve. Nurse will provi	de 60-minute po	st-infusion monitorin	g. Nurse	
I certify th	hat the use of the indicated tred	atment is medica	lly necessary and I v	vill be supervising	g the patient's treatm	nent.	
Prescriber Signature:					Date:		
		Prescribe	r Information				
Prescriber Name:			Phone:		Fax:		
Address:			NPI:				
City, State: Zip:			Office Contact:				
CONFIDENTIAL HEALTH INFORMATIO	N: Healthcare information is personal information	ation related to a person'	s healthcare. It is being faxed	to you after appropriate	authorization or under circums	tances that do not require	

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.